Asiye KANBAY, Ulukavak Tansu ÇİFTÇİ, Oğuz KÖKTÜRK

Could Obstructive Sleep Apnea Syndrome be a Component of Metabolic Syndrome?

Aim: Obstructive sleep apnea syndrome (OSAS) is a prevalent disorder and is associated with increased cardiovascular morbidity and mortality. OSAS is independently related to the cardiovascular risk factors that comprise metabolic syndrome, atherosclerosis, acute coronary syndrome, and sudden death. The prevalence of metabolic syndrome is 30%-40% in the Turkish population. However, there are no data about the prevalence of metabolic syndrome (MS) in Turkish patients with OSAS. The aim of this study was to determine the prevalence of MS in Turkish patients with OSAS and MS-related cardiovascular diseases. Materials and Methods: The medical records of patients who were admitted to our Sleep Disorders Center were evaluated retrospectively. OSAS was diagnosed by polysomnography (apnea-hypopnea index (AHI) >= 5). MS was diagnosed according to Adult Treatment Panel III. Individuals in whom AHI < 15 were recruited as group 1 and those in whom AHI >= 15 as group 2. Results: We studied 277 patients with OSAS (206 men and 71 women, aged 52.8 ± 9.8 years). The prevalence of MS in patients with OSAS was 39.71% (110 patients). This prevalence is higher than that in the Turkish population. The prevalence of MS in groups 1 and 2 was 25.5% and 74.5%, respectively (P < 0.005). Rates of MS were higher in patients with AHI >= 15 than in those with AHI < 15. In addition, the prevalence of hypertension, arrhythmia, atherosclerotic heart disease, and stroke in patients with and without MS was 73.5% and 26% (P = 0.00), 10.2% and 8.5% (P = 0.41), 42.5% and 18.3% (P = 0.00), and 3% and 0.06% (P = 0.23), respectively. Conclusions: The prevalence of MS is high in OSAS patients. In addition, the prevalence of MS is significantly high in patients with moderate-severe OSAS.

Anahtar Kelimeler:

Obstructive sleep apnea syndrome, metabolic syndrome, cardiovascular disease

Could Obstructive Sleep Apnea Syndrome be a Component of Metabolic Syndrome?

Keywords:

Obstructive sleep apnea syndrome, metabolic syndrome, cardiovascular disease,

PDF

___

1. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165: 1217-39.
2. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
3. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 2002; 166: 159-65.
4. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-84.
5. Tan KC, Chow WS, Lam JC, Lam B, Wong WK, Tam S et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006; 184: 377-82.
6. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670-6.
7. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-41.
8. Sogut A, Altin R, Uzun L, Ugur MB, Tomac N, Acun C et al. Prevalence of obstructive sleep apnea syndrome and associated symptoms in 3-11 year old Turkish children. Pediatr Pulmonol 2005; 39: 251-56.
9. Bayram F, Gundogan K, Ozturk A, Yazici C. Dunyada ve Turkiye’de Metabolik Sendromunun Dagilimi. Turk Klinikleri J Int Med Sci 2006; 2: 18-24.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
11. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages in Human Subjects. Los Angeles, CA: Brain Information Service, VCLA, 1968.
12. American Sleep Disorders Association. EEG arousals, scoring rules and examples: A preliminary report from the Sleep Disorders Atlas Task Force of the ASDA. Sleep 15: 173-184, 1992.
13. Sasanabe R, Banno K, Otake K, Hasegawa R, Usui K, Morita M et al. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. Hypertens Res 2006; 29: 315-22.
14. Kono M, Tatsumi K, Saibara T, Nakamura A, Tanabe N, Takiguchi Y et al. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007; 131: 1387-92.
15. Gruber A, Horwood F, Sithole J, Ali NJ, Idris I. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol 2006; 5: 22.
16. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-41.
17. Lavie P, Herer P, Peled R. Mortality seen in sleep apnea patients. A multivariate analysis of risk factors. Sleep 1995; 18: 157-179
18. Kraiczi H, Caidahl K, Samuelsson A, Peker Y, Hedner J. Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. Chest 2001; 119: 1085-91.
19. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE; Sleep Heart Health Study Investigators. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004; 160: 521-30.
20. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005; 172: 1590-5.
21. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-90.
22. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
23. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-76.